These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34431439)

  • 21. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development.
    Kaur H
    Crit Rev Biotechnol; 2021 Mar; 41(2):300-315. PubMed ID: 33430641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparability study of Rituximab originator and follow-on biopharmaceutical.
    Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK
    J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity.
    Beyer B; Walch N; Jungbauer A; Lingg N
    Biotechnol J; 2019 Apr; 14(4):e1800340. PubMed ID: 30315690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A rapid method for relative quantification of
    Segu Z; Stone T; Berdugo C; Roberts A; Doud E; Li Y
    MAbs; 2020; 12(1):1750794. PubMed ID: 32249667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and efficacy of biosimilars in oncology.
    Schellekens H; Smolen JS; Dicato M; Rifkin RM
    Lancet Oncol; 2016 Nov; 17(11):e502-e509. PubMed ID: 27819248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
    Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
    Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-glycosylation profile analysis of Trastuzumab biosimilar candidates by Normal Phase Liquid Chromatography and MALDI-TOF MS approaches.
    Sanchez-De Melo I; Grassi P; Ochoa F; Bolivar J; García-Cózar FJ; Durán-Ruiz MC
    J Proteomics; 2015 Sep; 127(Pt B):225-33. PubMed ID: 25907685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of glycoprofiles of rituximab versions licensed for sale in India and an analytical approach for quality assessment.
    Kaur T; Shukla BN; Yadav VK; Kulkarni MJ; Rao A
    J Proteomics; 2021 Jul; 244():104267. PubMed ID: 34015520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products.
    Tan Q; Guo Q; Fang C; Wang C; Li B; Wang H; Li J; Guo Y
    MAbs; 2012; 4(6):761-74. PubMed ID: 23032066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies.
    Derenne A; Derfoufi KM; Cowper B; Delporte C; Goormaghtigh E
    Anal Chim Acta; 2020 May; 1112():62-71. PubMed ID: 32334683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
    Nupur N; Chhabra N; Dash R; Rathore AS
    MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars for breast cancer.
    Migliavacca Zucchetti B; Nicolò E; Curigliano G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety concerns of biosimilar hormone products.
    Soldatov AA; Avdeeva JI; Kryuchkov NA; Skosyreva ES
    Curr Med Res Opin; 2019 Jun; 35(6):1003-1009. PubMed ID: 30466327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes.
    Gomes RA; Almeida C; Correia C; Guerreiro A; Simplício AL; Abreu IA; Alves PG
    PLoS One; 2019; 14(7):e0219156. PubMed ID: 31291294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biosimilars in the European Union: current situation and challenges].
    Wolff-Holz E; Weise M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Considerations related to comparative clinical studies for biosimilars.
    Rathore AS; Stevenson JG; Chhabra H
    Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.